Connor Clark & Lunn Investment Management Ltd. Has $87,000 Stock Position in Omeros Corporation $OMER

Key Points

• Connor Clark & Lunn Investment Management Ltd. reduced its stake in Omeros Corporation by 90.7%, bringing its holdings down to 10,555 shares worth $87,000.
• Omeros Corporation reported an earnings per share (EPS) of ($0.53) for the last quarter, beating estimates by $0.02, along with revenue of $28.60 million which significantly surpassed the consensus estimate.
• Research analysts have given Omeros an average rating of "Moderate Buy" with a target price of $18.00, despite mixed ratings from various firms.

Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in shares of Omeros Corporation (NASDAQ:OMER - Free Report) by 90.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,555 shares of the biopharmaceutical company's stock after selling 102,771 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Omeros were worth $87,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Deutsche Bank AG raised its position in Omeros by 4.9% during the first quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock valued at $345,000 after buying an additional 1,973 shares during the period. Vanguard Group Inc. increased its position in Omeros by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock worth $26,610,000 after purchasing an additional 95,599 shares during the last quarter. Harbour Investments Inc. increased its position in Omeros by 51.9% in the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 3,149 shares during the last quarter. Bank of New York Mellon Corp increased its position in Omeros by 2.2% in the 1st quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock worth $1,242,000 after purchasing an additional 3,321 shares during the last quarter. Finally, Sowell Financial Services LLC acquired a new position in Omeros in the 1st quarter worth about $88,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMER has been the topic of several research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $36.00 target price on shares of Omeros in a research report on Friday, August 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, August 15th. Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Omeros in a research report on Friday, June 27th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $18.00.

Omeros Stock Performance

OMER opened at $4.19 on Thursday. The company has a market cap of $285.17 million, a PE ratio of -1.99 and a beta of 2.26. The stock has a 50-day moving average of $3.62 and a 200-day moving average of $5.70. Omeros Corporation has a 52-week low of $2.95 and a 52-week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million for the quarter, compared to the consensus estimate of $0.31 million. On average, research analysts predict that Omeros Corporation will post -3.09 earnings per share for the current year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.